#COVAX

[ricisidro]

Pakistan will get 200,000 doses of #Pfizer’s new #COVID19 #vaccine from US and additional 300,000 more doses of Pfizer’s COVID-19 vaccine from #COVAX as the new JN.1 variant spreads. The COVID-19 jabs would be used to vaccinate high-risk groups.

#Omicron #JN1

https://www.geo.tv/latest/525298-pakistan-likely-to-get-updated-pfizer-covid-shots-as-new-variant-spreads

[gofitnesspro]

How to keep yourself safer and protected from the new COVID-19 Variant XBB.1.5 of 2023?

New COVID-19 Variant XBB.1.5 What is XBB.1.5? The New COVID-19 variant XBB.1.5 was discovered for the first time in the US in New York in October 2022. It is a recombinant or hybrid virus subvariant, which means it consists of two strains, in this case, two descendants of the Omicron BA.2 sub lineage. The XBB.1.5 variation features a mutation that virologists think makes the virus more capable…

[howdoesone]

How does one ensure equitable access to vaccines globally?

The COVID-19 pandemic has highlighted the importance of equitable access to vaccines as a global health imperative. Ensuring that vaccines are available to all individuals, regardless of their geographical location or socioeconomic status, is crucial for controlling the spread of infectious diseases and achieving global health security. This article explores the challenges in achieving equitable…

[sabersourcing]

Jawa's Junkyard Bright Star Lightsaber (Covax) | New Saber Alert

Jawa’s Junkyard Bright Star Lightsaber (Covax) | New Saber Alert

Jawa’s Junkyard Bright Star Lightsaber has been unveiled. The custom saber is inspired by the regal design of the ancient Lord Covax lightsaber, featuring a striking fan-shaped crossguard and an exposed kyber crystal. Jawa’s Junkyard offers the Bright Star lightsaber an empty hilt with two configurations: Static Mode (for display) or FX Mode (capable of accepting electronics). Jawa’s Junkyard…

[darkmaga-retard]

https://www.globalresearch.ca/the-covid-killer-vaccine-people-are-dying-all-over-the-world-its-a-criminal-undertaking/5800358

The Covid “Killer Vaccine”. People Are Dying All Over the World. It’s A Criminal Undertaking

By Prof Michel Chossudovsky

Global Research, September 18, 2024

We are being accused of  “spreading disinformation” regarding the Covid-19 vaccine. 

The Reuters and AP media “trackers” and “fact checkers” will be out to smear the testimonies of parents who have lost their children.  

“Once the Lie becomes the Truth, there is no moving backwards. Insanity prevails. The world is turned upside down.”

Let us be under no illusions, the Covid Jab is not only “experimental”, it’s a Big Pharma “killer vaccine” which modifies the human genome. The evidence of mortality and morbidity resulting from vaccine inoculation both present (official data) and future (e.g. undetected microscopic blood clots) is overwhelming. 

The official data (mortality and morbidity) as well as numerous scientific studies confirm the nature of the Covid-19 mRNA vaccine which is being imposed on all humanity. 

Peer reviewed reports confirm the causes  of vaccine related deaths and “adverse events” (injuries) including among others blood clots, thrombosis, myocarditis, cardiac arrests.

The stated objective is to enforce the Worldwide vaccination of 8 billion people in more than 190 countries, to be followed by the imposition of a digitized “vaccine passport”. Needless to say this is a multi-billion dollar operation for Big Pharma. It’s a crime against humanity.

The global vaccine project entitled COVAX is coordinated Worldwide by the WHO, GAVI, CEPI, the Bill and Melinda Gates Foundation in liaison with the World Economic Forum (WEF),  the Wellcome Trust, DARPA and Big Pharma which is increasingly dominated by the Pfizer-GSK partnership established barely four months before the onset of the Covid-19 crisis in early January 2020.  

The Covid 19 “Vaccine” from the very outset in January 2021 has been conducive to a Worldwide Upward Movement in Mortality 

[brightlotusmoon]

Remember when Chris Pine turned into a monster and ate Fred Savage in front of Richard Kind?

[allthebrazilianpolitics]

Brazilian-developed vaccine against Covid-19 registered by Anvisa

The new vaccine against Covid-19 developed by the Brazilian company Zalika Farmacêutica has been entered into the National Health Surveillance Agency (Anvisa) this week, Agencia Brasil reported. The drug can be used in people aged 12 and over and is to be administered in two doses, 21 days apart, with boosters after 6 months for those over 18 years of age.

The technology used in the Zalika vaccine is called “recombinant” because its molecules are formed by combining two different sources. In this case, the protein S antigen (spike) -capable of promoting a response from the immune system- and the saponin-based adjuvant allow the mixture to enhance the production of antibodies. This form of production brings greater safety to the pharmaceutical industry, Anvisa explained in a statement.

The new immunizer is the sixth to receive definitive individual registration from Anvisa, in addition to Comirnaty Ipfizer/Wyeth, Comirnaty bivalent (Pfizer), Janssen Vaccine (Janssen-Cila), Oxford/Covishield (Fiocruz and Astra-Zeneca) and Spikevax bivalent vaccines have received this type of authorization. Pfizer/Biontech, Astra-Zeneca, Janssen, Moderna, Sinopharm, and Sinovac also have definitive registration in the form of the Covax Facility consortium.

Continue reading.

[ultrajaphunter]

Emergency injunction and tribunal order was served to WHO and all Criminal Defendants

BREAKING NEWS:

Emergency injunction and tribunal order was served to WHO and all Criminal Defendants listed below to immediately cease and desist a criminal conspiracy to commit war crimes, genocide, crimes against humanity and to arrest and incarcerate these criminal defendants.

All Constitutional law enforcements officers worldwide are being served starting with Interpol and constitutional law enforcements in everyone of the 194 member nations under Writs of Mandamus ordering them to carry out their duties to arrest and incarcerate these criminal codefendants for unlawful and Genocidal acts in connection with the WHO Pandemic preparedness response and changes to the international health regulations.

Tribunal Writs of Mandamus is defined as:

“The lawful term writ of mandamus refers to an order by a court to a lesser government official to perform an act required by law, which he has refused or neglected to do.

This type of court order is a remedy that may be sought if a governmental agency, public authority, or corporation in service of the government, fails or refuses to do its public or statutory duty.”

This has been ordered by the Tribunal Under Articles 6 (Genocide) and 7 (Crimes Against Humanity) of the International Criminal Code.

List of Criminal Defendants 2009-2023 Lockstep Vaccination Genocidal Pandemic Criminal Co-conspiracy, including and not limited to individually and collectively:

Bill and Melinda Gates individually and the Bill and Melinda Gates Foundation.

World Health Organization (WHO) and Officers, Directors, Employees, and Agents Tedros Adhanom Ghebreyesus WHO Director General, Anthony Stephen Fauci.

World Economic Forum, Klaus Schwab and Officers, Directors, Employees, and Agents. Michael Bloomberg, David Rockefeller Jr, Warren Buffett, George Soros, Ted Turner, Oprah Winfrey, Rockefeller Foundation, Global Business Network (GBN), Peter Schwartz, Chairman GBN.

Convicted Vaccination Genocidal Pandemic and Neural Monitoring Governmental Executive Defendants: Xi JinPing, General Secretary of the Communist Party.

Vladimir Vladimirovich Putin, President of the Russian Federation. Donald J. Trump, 45th President of the United States of America. Joseph R. Biden 46th President of the United States of America.

Benjamin Netanyahu, Prime Minister of Israel. Boris Johnson, Prime Minister of the UK. Matt Hancock, UK Secretary of State for Health.

The Crown Corporation and any and all of its Subsidiaries including and not limited to Serco. Justin Trudeau, Prime Minister of Canada. Scott Morrison, Prime Minister of Australia. Jacinda Arden, Prime Minister of New Zealand.

Stefan Löfven Prime Minister of Sweden. Minister of Heath Lena Hallengren. Narendra Modi, Prime Minister of India.

Emmanuel Jean-Michel Frédéric Macron, President of France. Edouard Phillipe, Prime Minister of France.

Angela Merkel, Chancellor of Germany.

António Guterres, Secretary General of the United Nations Organization.

European Union, and President of the Commission, Ursula von der Leyen. President of the Parliament, David Sassoli. President of the European Council, Charles Michel. Michael Ryan, WHO CEO's at GCHQ-UK, NSA-USA and Bilderberg Group, all CEOs, Monarchies, and Members.

Convicted Defendant Pandemic Vaccine Programs: Global Alliance Vaccine Initiative [GAVI], The Vaccine Alliance, including and not limited to its Pandemic Vaccine Program.

Pandemic Vaccine Program United States of America, Operation Warp Speed and successor Pandemic Vaccine Program.

World Health Organization COVAX, Pandemic Vaccine Program. Pandemic Vaccine Program People's Republic of China, National Institutes for Food and Drug Control.

Russian Federation, Rospotrebnadzor.

Convicted Genocidal Vaccination Entities: Pfizer, AstraZeneca, Moderna, Johnson and Johnson, The Pirbright Institute.

02/24/23 Judge Pascal Najadi:

They will all be arrested as soon as possible, Military and law enforcement worldwide are preparing for this to happen. Godspeed.

[reasonsforhope]

“The development of covid-19 vaccines was a scientific triumph. Converting it into medical benefits has required getting shots into the arms of as many people as possible, a process fraught with political and logistical hurdles. Nonetheless, a new study finds that jabs cut the disease’s death toll by 63% during their first year.

To calculate the number of lives saved by vaccines, researchers at Imperial College London needed to estimate how many people would have died without the jabs. They simulated this scenario using an epidemiological model, which calculates the shares of the population that are susceptible to a disease; get exposed; get infected; die or recover; and are vulnerable to reinfection. Each of these rates depends on factors like the transmissibility and severity of the pathogen, how much people interact with each other, demography, health-care quality and, crucially, vaccination...

The study also found that vaccines helped rich and poor alike. Rich countries gobbled up 2.5 times as many doses per person as did the poor ones covered by Covax, a jab-distribution scheme, but the paper found that nearly as many deaths were prevented in the Covax countries (around 7m) as in rich ones (roughly 8m). This is proportional to the number of people in these groups of countries aged at least 65, who are most at risk from covid.” -via The Economist, via Future Crunch

[dapurinthos]

an underworld (under-temple) ADVENTURE moment aka me rubbing my hands together in utter glee at getting to write the sith shrine below the temple. no, not the shrine in the depths that everyone thinks was the sith temple that's been purified. the one below that. the one that's seeping darkness upward through coruscant.

The first thing to draw the eye is the fire. It flickers and glows in a circle atop what looks like a pedestal formed out of the bedrock. It looks like the beginning of a stalagmite, only the base remaining while the higher rock, and more, has been removed to create an imitation of a natural formation. Its top is too regular to be one, below that circle of red flame that does not touch its surface. Red is a normal fire colour. It’s the coldest part of a flame. But that red leans toward orange, which it turns into as the fire gets hotter. These flames are red in an unnatural way that only underlies the screaming from the object they circle: a cluster of kyber similar in form to the healing crystals kept under lock and key by the Circle of Jedi Healers but on a scale that far outpaces theirs. Its facets reflect the flames in such a way that it looks like something inside the crystal is dancing. The kyber is just as red and just as terrible as the soundless flames surrounding—containing? Trapping?—it. If it remains in the kyberite druse it was formed in, that lies below the surface of whatever the shorn rock holds in its basin. It shimmers as well, reflecting its companions liquidly. It’s all red. All blood. Not the kind most people are familiar with, venous blood that’s dark from losing oxygen, the kind that gets drawn out at you at the doctor’s. This is the red of the artery, bright and almost unreal, plastic-y, in its colour. A Sith’s kyber crystal is described as bloodshine for a reason. I stare at this one and swear that I can see it throbbing like a heart laid bare after being carved free. It kicks at something at the back of my mind, a rabbit’s foot thumping the ground in warning of something older and darker than anything that even Lene has seen in her explorations.

picking up the clone wars sketches for the unmade sith shrine arc, adding in lady covax's fortress on mustafar (which looks like it was inspired from those concept sketches), the wellspring of the force planet, & momin's cave (which i actually didn't look at until after deciding the 'wellspring' coming out of the ground like a scooped-out stalagmite).

[ricisidro]

View this post on Instagram

A post shared by Jun Isidro (@rcisidro)

Negotiations with #COVAX for about 2 million #bivalent vaccine doses against #COVID19 are ongoing, said Health Secretary Teodoro Herbosa today June 21, 2023.

#Philippines #DOH

[industryforecastnews]

Vaccine Market To Reach USD 110.54 Billion By 2030

Vaccine Market Growth & Trends

The global vaccine market size is expected to reach USD 110.54 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.74% from 2024 to 2030. The growth is attributed to the rising immunization programmes, and the development of vaccines for diseases, such as RSV and Chlamydia amongst others. There has been significant progress in improving access to vaccines for diseases of public health concern. Many new vaccines have been developed and distributed globally, resulting in the saving of countless lives and the prevention of various illnesses.

Furthermore, there are several initiatives in the vaccine market aimed at improving access to vaccines, developing new vaccines, and ensuring vaccine safety. These initiatives involve international organizations, governments, private sector entities, and philanthropic organizations. Through collaboration and innovation, these initiatives are helping to address global health challenges and improve public health outcomes. For instance, COVAX is a global initiative aimed at ensuring equitable access to COVID vaccines. The initiative is co-led by Gavi, the Vaccine Alliance, the World Health Organization (WHO), and the Coalition for Epidemic Preparedness Innovations (CEPI).

Although there are over 90 vaccine manufacturers supplying vaccines to World Health Organization Member States in 2021, supply remains highly dependent on fewer than 10 manufacturers with diverse deployable technology and global reach. This concentration leads to regional supply insecurity and market health issues, particularly in the African and Eastern Mediterranean regions. It is anticipated that the COVID vaccine market could go private in the second half of 2023 in the U.S. This privatization may lead to an increase in prices of COVID vaccines and open up the market for other players as well. For instance, both Moderna and Pfizer BioNTech have announced that the prices of their respective mRNA COVID vaccines could increase to around USD 110 to USD 130 per shot.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/vaccine-market

Vaccine Market Report Highlights

By type, the mRNA segment dominated the vaccine market with a share of 32.32% in 2023. However, the subunit vaccine segment is expected to grow at the fastest CAGR of 8.1% during the forecast period

By route of administration, the parenteral administration is anticipated to capture the majority of the vaccine market share throughout the forecast period. Parenteral administration reduces the risk of contamination compared to other routes of administration thus contributing to the segments’ dominance

By disease indication, the viral diseases segment captured the largest share of the vaccine market in 2023, majorly attributed to the high distribution of COVID-19 vaccines during 2021 and 2022

By age, pediatrics is expected to witness the fastest growth during the forecast period, as many countries have established national immunization programs that require children to receive certain shots as part of routine childhood vaccinations

By distribution channel, pharmacies are anticipated to be the fastest-growing segment. This growth can be attributed to the increased accessibility and convenience for patients, and the potential for increased revenue and profitability for pharmacies

North America region is expected to grow at the fastest CAGR during the forecast period. The region is dominated by a few key players, including Pfizer, Moderna, Sanofi Pasteur, and Merck. These companies have a strong presence in the market, with established distribution networks and significant investment in vaccine research and development

Vaccine Market Segmentation

Grand View Research has segmented the global vaccine market on the basis of type, route of administration, disease indication, age group, distribution channel, and region

Vaccine Type Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Subunit Vaccines

Recombinant vaccines

Conjugate Vaccines

Toxoid vaccines

Inactivated

Live Attenuated

mRNA vaccines

Viral vector vaccines

Vaccine Route Of Administration Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Oral

Parenteral

Nasal

Vaccine Disease Indication Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Viral Diseases

Hepatitis

Influenza

HPV

MMR

Rotavirus

Herpes Zoster

Covid-19

Others

Bacterial Vaccines

Meningococcal Diseases

Pneumococcal diseases

DPT

Others

Cancer Vaccines

Allergy Vaccines

Vaccine Age Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Pediatric

Adult

Vaccine Distribution Channel Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Hospital & Retail Pharmacies

Government Suppliers

Others

Vaccine Regional Outlook (Revenue, USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players in the Vaccine Market

Serum Institute of India Pvt. Ltd.

Seqirus

Sanofi

GSK Plc.

Merck & Co., Inc.

Pfizer Inc.

Moderna Inc.

Sinovac

BioNTech SE

AstraZeneca

Browse Full report: https://www.grandviewresearch.com/industry-analysis/vaccine-market

[schoje]

A Comissão Parlamentar de Inquérito (CPI) da Pandemia do Senado ouve, nesta terça-feira (18), o ex-ministro das Relações Exteriores Ernesto Araújo, sétimo a falar ao colegiado. Desde as 9h30 da manhã, Araújo tem respondido a perguntas sobre a condução da diplomacia brasileira durante a pandemia, com foco na relação do Brasil com a China e nas negociações para compras de vacina. O ex-ministro negou que tenha causado qualquer atrito com a China “antes ou durante a pandemia” e que isso tenha dificultado a aquisição de vacinas para o Brasil. “Não entendo nenhuma declaração que eu tenha feito em nenhum momento como antichinesa. Houve determinados momentos em que, como se sabe, por notas oficiais, o Itamaraty, eu tomei a decisão, nós nos queixamos de comportamentos da Embaixada da China ou do embaixador da China em Brasília, mas não houve nenhuma declaração que se possa qualificar como antichinesa. Não há nenhum impacto de algo que não existiu”, declarou. Segundo Ernesto Araújo, o Itamaraty acompanhou os trâmites burocráticos dos insumos para as vacinas, mas não foi identificada nenhuma correlação entre atraso dos insumos e declarações do governo brasileiro. Saída do governo Ao falar de sua saída do posto de chanceler brasileiro, ocorrida em março deste ano, o diplomata disse que o fato não teve qualquer relação com a questão das vacinas. “Certamente não foi a questão de vacinas, como foi falado. O presidente manifestou que havia surgido, a partir de determinados fatos, dificuldades que poderiam dificultar o relacionamento, especificamente com o Senado e diante disso me pediu que colocasse a disposição o cargo, o que eu fiz”, afirmou. Araújo afirmou que ainda em 2020 o Ministério das Relações Exteriores (MRE) já havia instruído postos diplomáticos brasileiros a prospectar estudos no exterior, sempre em parceria com a pasta da Saúde, com a qual tinha bom relacionamento, seja a gestão de Luiz Henrique Mandetta, sejam as de Nelson Teich e Eduardo Pazuello. Estados Unidos Perguntado se declarações do governo brasileiro mal recebidas pela China tinham a ver com um alinhamento à política internacional norte-americana de Donald Trump, Ernesto Araújo disse que não. Ainda sobre o governo Trump, disse que o que houve foi uma "aproximação", mas que a relação não trouxe benefícios à imunização de brasileiros visto que os Estados Unidos proibiram a exportação de vacinas. De acordo com Araújo, com Joe Biden na Presidência dos Estados Unidos, houve mudança de ênfase por parte do governo americano, mas havia contato estreito e frutífero com o novo governo, para rearmar a relação a partir das novas prioridades do governo americano. Cloroquina O relator Renan Calheiros (MDB-AL) pediu explicações ao diplomata sobre a aquisição de hidroxicloroquina pelo governo brasileiro. O ex-ministro disse que em março de 2020 havia uma expectativa de que houvesse eficácia com o uso da cloroquina, não só no Brasil, mas no mundo. “Os estoques de cloroquina baixaram e ajudamos a viabilizar. É um remédio necessário, usado para outras doenças crônicas, e o estoque havia baixado”, explicou. Covax Facility Sobre a decisão do Brasil de obter o equivalente a 10% da população brasileira de doses de vacinas pelo consórcio internacional Covax Facility – iniciativa da Organização Mundial da Saúde (OMS) para o fornecimento de imunizantes para o mundo –, o diplomata relatou que houve uma reunião na Casa Civil para analisar a entrada do Brasil no grupo. Segundo Araújo, partiu do Ministério da Saúde a decisão sobre a porcentagem de doses, que poderia ter sido de até 50%. “Jamais fui contra [o consórcio internacional], o Itamaraty esteve atento desde abril de 2020, assim que o Covax tomou forma, em julho, assinei carta para o gestor do consórcio dizendo que o Brasil tinha interesse em entrar. O contrato ficou pronto em setembro e assinamos naquele momento”, disse Araújo. O contrato resultou na aquisição de 2,9 milhões de doses de vacinas para os brasileiros.

[warningsine]

Immunisation is considered one of the most cost-effective public health interventions, saving millions of lives each year, and benefiting the health of the wider community through herd immunity.

Yet, there is as much reason to worry as to celebrate. During the COVID-19 pandemic, the world witnessed a strong disruption in routine immunisation, leading to an increase in outbreaks of diphtheria, measles, polio, and yellow fever in over 100 countries. On the one hand, this can be explained by challenges with the supply of vaccines and the reduced availability of healthcare workers due to confinement policies, illness, and the diversion of activities to COVID-19.

But declining confidence in vaccines also played a role. Indeed, vaccine hesitancy, the reluctance or refusal to vaccinate, is a key barrier to immunisation and a major threat to global health.

Some make the case that vaccine demand can be actively promoted through communication campaigns. While there is a large body of evidence on what and how to communicate, less is known about who should communicate.

Recent studies from the US suggest that the public vaccination of high-profile politicians may boost vaccine confidence.

But systematic information on such vaccine role modelling is lacking. And it’s unclear to what extent results apply in different settings.

In a recently published study we set out to close these gaps.

We used the Democratic Republic of Congo as our case study. Vaccine confidence strongly declined in this country during the COVID-19 pandemic. This is acause for concern, as Africa is already lagging behind the rest of the world in achieving universal vaccination coverage.

Our focus was to understand the extent to which the vaccination of a president in public view increased vaccine uptake.

We concluded from our findings that it does, but under two conditions. Firstly, citizens must see the president as trustworthy. And secondly, the president’s vaccination must be communicated as widely as possible and include parts of the country or communities where there is low media access.

Where these two conditions aren’t met, vaccinating public village leaders or respected older adult community members might be a more effective approach to increasing vaccine uptake.

Presidents and vaccines

We found that around the world, 168 out of 173 leaders explicitly supported the COVID-19 vaccination campaign, 139 leaders (80%) made their own COVID-19 vaccination public and 108 leaders (78% of those vaccinated) distributed a picture or video of their vaccination.

President Felix Tshisekedi of the DRC received his COVID-19 vaccine live on Congolese television on 13 September 2021.

Vaccination rates in the country were low. By March 2022, only 5.7% of the population had received at least one vaccine dose, and just 1.03% were fully vaccinated. A number of factors were behind these low numbers:

low confidence in COVID-19 vaccines

a combination of limited healthcare services, poor transport infrastructure, and concerns about the safety of the AstraZenica vaccine, making the DRC unable to use most of the 1.7 million vaccine doses it received under the global Covax scheme for poorer countries

broader governance issues, including rampant corruption and political instability.

DR Congo is ranked near the bottom of the Human Development Index, occupying place 180 out of 193 countries. This indicates low levels of health, education and income. Our research took place in the country’s east, which has been plagued by violence for over two decades.

In addition, the region was facing an outbreak of the Ebola virus disease when COVID-19 hit.

Within this context, we analysed the potential of President Tshisekedi to act as a vaccine ambassador and influence COVID-19 vaccine uptake.

In September 2021, we conducted a survey with 600 people in six villages of Lubero territory, in the province of North Kivu. Lubero is a remote and mostly rural area with poor public infrastructure and little access to media or news outlets. COVID-19 vaccines were not yet available in the study area.

Our survey started before Tshisekedi got vaccinated.

We asked: “Let’s assume a vaccine against coronavirus was available for you; would you take it?”.

While 98% of respondents said they had vaccinated their children against diseases such as tuberculosis, polio or measles, only 22% indicated they would accept a COVID-19 vaccine.

From answers to open questions we learned that this mismatch can largely be explained by respondents’ general lack of trust in the COVID-19 vaccine and its efficacy, and the fear of potentially mortal side-effects.

We further found low levels of institutional trust. Only 17% of respondents indicated they trusted the president when asked to what extent they believed he represented the best interests of the Congolese population.

Respondents also reported low phone ownership and access to media. In the week prior to the survey, 91% of respondents did not watch television and 57% did not listen to the radio.

Prior to asking about COVID-19 vaccine acceptance, a random third of respondents received the prompt: “Assume the president, Félix Tshisekedi, were to take the vaccine live on television”.

We measured the impact of this prompt by comparing respondents’ stated vaccine acceptance to that of a randomly selected control group and found that trust moderated the results. For those who reported trusting the president, we found that the survey experiment boosted vaccine acceptance by 25 percentage points. Instead, for those who mistrusted the president, vaccine acceptance was lower among those who saw the prompt, by 6 percentage points.

To our surprise, the president got publicly vaccinated while our survey was in progress. Given low media access in our study region, only 18% of those interviewed after the broadcasting of Tshisekedi’s vaccination reported being aware of it. When comparing respondents with similar socio-economic profiles, access to media and levels of trust, we found that being aware of the president’s vaccination increased vaccine acceptance by 20 percentage points.

Policy implications

Our findings highlight that to serve as a vaccination model:

the leader should be perceived as trustworthy by citizens

the vaccination should be widely communicated.

When trust in national leaders is lacking, or news on their actions is inaccessible, other leaders might be more effective in boosting vaccine acceptance.

[deblala]

The Transhumanist Covax Agenda

https://www.infowars.com/posts/the-transhumanist-covax-agenda/

[yourusatoday]

Navigating the Dynamics of the COVID-19 Vaccines Market: A Comprehensive Analysis

Introduction: Understanding the Landscape of the COVID-19 Vaccines Market

The COVID-19 pandemic has catalyzed an unprecedented global response, prompting pharmaceutical companies, governments, and healthcare organizations to expedite the development, production, and distribution of vaccines to curb the spread of the virus. As the world grapples with the challenges posed by the pandemic, the COVID-19 vaccines market emerges as a focal point of innovation, collaboration, and public health intervention.

Unraveling the Nuances: Key Insights into the COVID-19 Vaccines Market

Market Overview

The COVID-19 vaccines market is characterized by dynamic shifts in supply and demand dynamics, regulatory frameworks, and geopolitical considerations. With multiple vaccine candidates receiving emergency use authorization and regulatory approval, the market experiences a surge in production capacity, distribution networks, and global vaccination campaigns aimed at achieving herd immunity and containing the spread of the virus.

Market Dynamics

The dynamics of the COVID-19 vaccines market are influenced by a myriad of factors, including vaccine efficacy, safety profiles, manufacturing capabilities, procurement strategies, and public acceptance. Pharmaceutical companies engage in rigorous clinical trials, real-world evidence studies, and post-market surveillance to assess vaccine performance, monitor adverse events, and address emerging challenges related to vaccine efficacy, durability of protection, and variant strains of the virus.

Regulatory Landscape

Regulatory agencies play a pivotal role in ensuring the safety, efficacy, and quality of COVID-19 vaccines through rigorous assessment, approval, and post-market surveillance mechanisms. Collaborative initiatives such as the World Health Organization's Emergency Use Listing (EUL) and the European Medicines Agency's Conditional Marketing Authorization (CMA) facilitate expedited regulatory pathways for vaccine authorization, enabling timely access to safe and effective vaccines for global populations.

Emerging Trends

Technological advancements and scientific innovations drive emerging trends in the COVID-19 vaccines market, including the development of next-generation mRNA vaccines, viral vector vaccines, protein subunit vaccines, and nanoparticle-based vaccine platforms. Additionally, the adoption of novel vaccine delivery systems, cold chain logistics solutions, and digital health technologies enhances vaccine accessibility, distribution efficiency, and vaccination coverage in diverse healthcare settings.

Navigating Challenges: Addressing Key Issues in the COVID-19 Vaccines Market

Vaccine Equity and Access

Despite significant progress in vaccine development and deployment, disparities in vaccine access and distribution persist across regions, countries, and socioeconomic groups. Global initiatives such as the COVAX Facility and bilateral agreements between governments and vaccine manufacturers aim to address vaccine inequities, promote vaccine sharing, and accelerate immunization efforts in low- and middle-income countries with limited access to vaccines.

Vaccine Hesitancy and Misinformation

Vaccine hesitancy and misinformation pose significant challenges to public health efforts aimed at achieving widespread vaccine coverage and community immunity. Addressing vaccine hesitancy requires targeted communication strategies, community engagement initiatives, and transparent dissemination of accurate information regarding vaccine safety, efficacy, and public health benefits to build trust and confidence in vaccination programs.

Variants and Vaccine Efficacy

The emergence of SARS-CoV-2 variants presents ongoing challenges to vaccine efficacy, immune escape, and pandemic control efforts. Continuous surveillance, genomic sequencing, and epidemiological monitoring enable early detection of variant strains and informed decision-making regarding vaccine development, booster doses, and public health interventions to mitigate the spread of variant viruses and prevent resurgence of COVID-19 outbreaks.

Buy the Report to Get Full Access to the COVID-19 Vaccines Market Forecast or Download a Free Report Sample

Embracing Opportunities: Strategies for Advancing the COVID-19 Vaccines Market

Global Collaboration and Partnerships

Collaborative partnerships among governments, pharmaceutical companies, international organizations, and civil society stakeholders are essential to enhance vaccine research, development, manufacturing, and distribution capacities on a global scale. Multilateral initiatives foster knowledge sharing, technology transfer, and capacity-building efforts to address supply chain bottlenecks, expand production capacity, and ensure equitable access to COVID-19 vaccines for all populations.

Innovation and Research

Investments in vaccine research, development, and innovation drive scientific advancements and technological breakthroughs in vaccine design, formulation, and delivery systems. Novel vaccine platforms, adjuvants, and antigen designs hold promise for enhancing vaccine efficacy, durability of immune responses, and cross-protective immunity against emerging variants of concern, laying the foundation for future pandemic preparedness and response efforts.

Conclusion: Charting the Course for Success in the COVID-19 Vaccines Market

In conclusion, the COVID-19 vaccines market represents a pivotal nexus of science, public health, and global cooperation in combating the pandemic and safeguarding human health and well-being. By navigating the complexities of vaccine development, regulatory approval, distribution logistics, and public health communication, stakeholders can collectively address challenges, capitalize on opportunities, and accelerate progress towards achieving universal access to safe, effective, and affordable COVID-19 vaccines for a healthier and more resilient future.